Barristers and Solicitors/Patent and Trade Mark Agents Practice Restricted to Intellectual Property Law

January 9, 2002

Micheline Gravelle B.Sc., M.Sc. (Immunol.) 416 957 1682 mgravelle@bereskinparr.com

Your Reference: Our Reference: 09/926,036 12536-2

Commissioner for Patents United States Patent and Trademark Office Washington, D.C. 20231 U.S.A.

Attention: Box PCT

Dear Sir:

Re: RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS UNDER

35 U.S.C. 371

United States Patent Application No. 09/926,036 Entitled: A Caspase Activated Protein Kinase Inventors: Michael A. Rudnicki and Luc A. Sabourn

I.A. Filing Date: February 18, 2000

This is in response to the Notification of Missing Requirements Under 35 U.S.C. 371 mailed October 10, 2001, a copy of which we attach. Applicants are simultaneously filing a Petition for Extension of Time under 37 CFR 1.136(a) to respond to the Notification of Missing Requirements.

Please amend the application as follows:

## In the Specification

Please replace the paragraphs beginning at page 6, line 25, with the following rewritten paragraphs:

Figure 1 (SEQ.ID.NOS: 1 and 2) shows the cDNA sequence of SMAK.

Figure 2 (SEQ.ID.NO: 2) shows the deduced amino acid sequence of SMAK.

Figure 3A shows the sequence alignment of SMAK (SEQ.ID.NO: 3) with that of the Ste20-related kinases human SLK (hSLK) (SEQ.ID.NO: 4), LOK (SEQ.ID.NO: 5) and MST (SEQ.ID.NO: 6).

Figure 3B shows the sequence alignment of SMAK (SEQ.ID.NO: 7) with Rat SLK (SEQ.ID.NO: 8), LOK (SEQ.ID.NO: 9), M-NAP (SEQ.ID.NO: 10) and AT1-46 (SEQ.ID.NO: 11).